- Home
- CALC vs RNXT Comparison
CALC vs RNXT Comparison
Compare CALC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- RNXT
- Stock Information
- Founded
- CALC 2011
- RNXT 2012
- Country
- CALC United States
- RNXT United States
- Employees
- CALC N/A
- RNXT N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- RNXT Health Care
- Exchange
- CALC Nasdaq
- RNXT Nasdaq
- Market Cap
- CALC 22.9M
- RNXT 44.6M
- IPO Year
- CALC N/A
- RNXT 2021
- Fundamental
- Price
- CALC $1.58
- RNXT $1.30
- Analyst Decision
- CALC Strong Buy
- RNXT Strong Buy
- Analyst Count
- CALC 3
- RNXT 2
- Target Price
- CALC $16.33
- RNXT $7.25
- AVG Volume (30 Days)
- CALC 28.9K
- RNXT 145.6K
- Earning Date
- CALC 08-11-2025
- RNXT 08-12-2025
- Dividend Yield
- CALC N/A
- RNXT N/A
- EPS Growth
- CALC N/A
- RNXT N/A
- EPS
- CALC N/A
- RNXT N/A
- Revenue
- CALC N/A
- RNXT $240,000.00
- Revenue This Year
- CALC N/A
- RNXT $3,186.05
- Revenue Next Year
- CALC N/A
- RNXT $291.93
- P/E Ratio
- CALC N/A
- RNXT N/A
- Revenue Growth
- CALC N/A
- RNXT N/A
- 52 Week Low
- CALC $1.42
- RNXT $0.75
- 52 Week High
- CALC $5.97
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- CALC 44.94
- RNXT 49.27
- Support Level
- CALC $1.42
- RNXT $1.27
- Resistance Level
- CALC $1.85
- RNXT $1.42
- Average True Range (ATR)
- CALC 0.15
- RNXT 0.06
- MACD
- CALC -0.01
- RNXT -0.02
- Stochastic Oscillator
- CALC 37.21
- RNXT 25.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.